Studies related to Fecal Bile Acids and Lactobacillus reuteri

Cholesterol-lowering Efficacy Of A Microencapsulated Bile Salt Hydrolase-active Lactobacillus Reuteri NCIMB 30242 Yoghurt Formulation In Hypercholesterolaemic Adults

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 114
Gender Both Genders
Age Range 30-44, 45-64
Body Types Overweight
Notes for this study:
_L. reuteri_ NCIMB at 5x10^9^ CFU daily for six weeks in persons with high cholesterol was able to moderately reduce both LDL cholesterol (8.92%) and total cholesterol (4.81%) with no influence on fecal bile acids nor other parameters of cardiovascular health.

Safety testing found supplementation to be well tolerated.
Funding issues for this study:
Some authors reported a potential conflict of interest as they are involved with the company which produces this strain (Micropharma limited)